Astrocytoma (Brain Glioma)

An astrocytoma is a type of brain tumour arising from astrocytes — the glial support cells of the brain and spinal cord. Astrocytomas range from slow-growing low-grade lesions (such as pilocytic astrocytoma in children) to more aggressive diffuse and anaplastic forms in adults. Under the WHO 2021 classification, they are now defined by molecular markers such as IDH mutation status, not just by microscopic appearance.

Symptoms depend on the tumour's location in the brain. New-onset seizures are one of the most common presentations, particularly for frontal and temporal lobe tumours. Headaches — especially those that worsen over time — progressive focal weakness, speech difficulty, vision changes, and personality or cognitive changes may also occur. Low-grade tumours may produce subtle symptoms for months to years before diagnosis.

MRI of the brain with gadolinium contrast is the primary imaging tool. Definitive diagnosis requires surgical resection or biopsy, followed by neuropathological analysis. Critically, molecular testing — IDH1/2 mutation, MGMT methylation, ATRX loss, 1p/19q codeletion, and CDKN2A/B deletion — must be performed to classify the tumour correctly under WHO 2021 criteria and to guide treatment decisions.

IDH (isocitrate dehydrogenase) mutation is the most important molecular marker in diffuse astrocytomas. IDH-mutant astrocytomas have a significantly better prognosis than IDH-wildtype glioblastoma and a distinct biology that makes them candidates for IDH-targeted therapies such as vorasidenib. IDH mutation also defines the WHO 2021 diagnostic category — all diffuse astrocytomas must be tested for IDH status.

Treatment depends on grade, IDH status, MGMT methylation, and patient factors. Surgery is the first step whenever safe. For low-grade IDH-mutant astrocytomas, surgery followed by surveillance or vorasidenib is increasingly used. For grade 3–4, radiotherapy combined with temozolomide chemotherapy is standard. MGMT-methylated tumours benefit most from temozolomide. Proton therapy may be offered at specialist centres for selected patients.

Vorasidenib is a brain-penetrant oral IDH1/2 inhibitor that crosses the blood-brain barrier and specifically targets the IDH mutation found in most diffuse astrocytomas. The INDIGO trial showed it significantly delayed progression in adults with residual or recurrent IDH-mutant grade 2 diffuse glioma after surgery alone. It was approved in 2024 and represents the first targeted oral therapy specifically for this population.

Proton therapy delivers radiation that stops at a defined depth in tissue (the Bragg peak), reducing unnecessary dose to surrounding normal brain. This dosimetric advantage is most significant for children, young adults where late cognitive effects matter most, and for tumours near critical structures. Proton therapy is not universally available and requires specialist centre assessment to confirm eligibility. CancerFax can assist in identifying and accessing proton therapy centres internationally.

Yes. Diffuse and anaplastic astrocytomas typically recur despite initial treatment, often at or near the original site. Recurrence monitoring requires regular MRI surveillance. At recurrence, options include re-resection, re-irradiation (stereotactic), alternative chemotherapy, and participation in clinical trials for IDH inhibitors or other targeted agents. Distinguishing true recurrence from pseudoprogression (treatment-related imaging changes) is a critical clinical challenge that specialist neuro-oncology expertise helps navigate.

Yes. CancerFax supports patients with astrocytoma by reviewing MRI reports and neuropathology data, coordinating specialist neuro-oncology second opinions, confirming molecular profiling (IDH, MGMT, CDKN2A/B), and identifying access to advanced therapies including vorasidenib, IDH inhibitor trials, BRAF-targeted therapy for BRAF-altered tumours, and proton beam radiotherapy at specialist centres in China and globally.

For patients outside countries where vorasidenib or other approved agents are available, CancerFax can assist with cross-border access coordination and clinical trial enrolment support.